Amlodipine Drug-Drug Interactions: A Complete Clinical Profile

How Amlodipine Is Metabolized and Why That Matters for Interactions

Amlodipine is a dihydropyridine calcium channel blocker that reaches peak plasma concentrations 6 to 12 hours after oral dosing and carries one of the longest half-lives in its class at 30 to 50 hours. The liver converts roughly 90% of absorbed amlodipine into inactive pyridine metabolites, with CYP3A4 serving as the dominant enzyme.

This CYP3A4 dependence creates a predictable interaction surface. Any drug that inhibits CYP3A4 can slow amlodipine clearance, raising plasma levels and intensifying both its blood-pressure-lowering effect and side effects like ankle edema. Conversely, CYP3A4 inducers accelerate metabolism and may render standard doses ineffective. Because amlodipine's half-life is already long, changes in clearance can take 7 to 10 days to reach a new steady state, meaning interactions may not become clinically apparent during the first few days of co-prescribing. A pharmacokinetic analysis published in Clinical Pharmacology & Therapeutics confirmed that CYP3A4 is responsible for more than 90% of amlodipine's oxidative metabolism, with CYP3A5 contributing a minor fraction.

Amlodipine is also 97.5% protein-bound to albumin. Despite this high binding fraction, clinically meaningful displacement interactions have not been documented because the drug's volume of distribution is large (roughly 21 L/kg). The practical takeaway: interactions with amlodipine are almost entirely enzymatic, not protein-binding driven.

CYP3A4 Inhibitors: The Highest-Risk Category

Strong CYP3A4 inhibitors produce the largest increases in amlodipine exposure. Clinicians should anticipate enhanced hypotension, reflex tachycardia, dizziness, and peripheral edema when pairing amlodipine with these agents.

Azole antifungals. Ketoconazole and itraconazole are potent CYP3A4 inhibitors. A pharmacokinetic study demonstrated that ketoconazole 200 mg twice daily increased amlodipine AUC by approximately 80% in healthy volunteers. Itraconazole produces similar effects. Fluconazole is a moderate inhibitor and raises amlodipine levels to a lesser degree, though dose adjustment may still be warranted in older adults or those on higher amlodipine doses.

Macrolide antibiotics. Clarithromycin and erythromycin inhibit CYP3A4 and can increase amlodipine concentrations. A population-based cohort study in Ontario found that older adults prescribed clarithromycin with a calcium channel blocker had a significantly higher rate of hospitalization for hypotension compared to those given azithromycin (which does not inhibit CYP3A4). The adjusted odds ratio was 3.7 for hypotension-related admission.

HIV protease inhibitors. Ritonavir, a pharmacokinetic booster in many antiretroviral regimens, is among the strongest CYP3A4 inhibitors in clinical use. The FDA label for amlodipine specifically notes that co-administration with CYP3A4 inhibitors may require dose reduction. Starting amlodipine at 2.5 mg daily and titrating slowly is a reasonable strategy in patients on ritonavir-boosted regimens.

Diltiazem and verapamil. These non-dihydropyridine calcium channel blockers inhibit CYP3A4 while also exerting additive pharmacodynamic effects on heart rate and blood pressure. Combining amlodipine with diltiazem can increase amlodipine exposure by approximately 50% and simultaneously slow AV-nodal conduction. This pairing is not routinely recommended and requires careful hemodynamic monitoring when used.

CYP3A4 Inducers: Loss of Blood-Pressure Control

Strong CYP3A4 inducers accelerate amlodipine metabolism and can reduce drug exposure enough to compromise blood-pressure control. Rifampin is the archetypal inducer; a crossover study in healthy subjects showed that rifampin 600 mg daily for 11 days decreased amlodipine AUC by approximately 60% and reduced peak plasma concentration by a similar magnitude.

Other clinically relevant inducers include carbamazepine, phenytoin, phenobarbital, and St. John's wort. Patients starting any of these while on amlodipine may need dose escalation or a switch to a calcium channel blocker with a different metabolic pathway. Blood-pressure monitoring should intensify during the first two weeks of co-administration, because full induction typically develops over 7 to 14 days.

Dexamethasone at chronic high doses also induces CYP3A4, though the magnitude is smaller than rifampin. Short courses for acute conditions are unlikely to meaningfully alter amlodipine pharmacokinetics.

The Simvastatin Interaction: An FDA-Mandated Dose Cap

The interaction between amlodipine and simvastatin is one of the most frequently cited in clinical practice. Amlodipine inhibits the CYP3A4-mediated metabolism of simvastatin, raising simvastatin acid AUC by approximately 77%.

The clinical consequence is an elevated risk of simvastatin-induced myopathy and rhabdomyolysis. In 2011, the FDA issued a drug safety communication restricting simvastatin to a maximum of 20 mg daily when used with amlodipine. This cap applies regardless of patient size or cholesterol burden.

Atorvastatin is also a CYP3A4 substrate, but its interaction with amlodipine is more modest. One study found an 18% increase in atorvastatin AUC with amlodipine co-administration, a magnitude that does not necessitate a dose cap. Rosuvastatin and pitavastatin are not metabolized by CYP3A4 and carry no pharmacokinetic interaction with amlodipine. For patients requiring high-intensity statin therapy alongside amlodipine, rosuvastatin or atorvastatin are preferred alternatives to simvastatin.

Dr. Robert Giugliano of Brigham and Women's Hospital has noted: "The simvastatin dose cap with amlodipine is one of the most overlooked prescribing restrictions in cardiology. Switching to rosuvastatin eliminates the issue entirely without compromising LDL reduction."

Cyclosporine: A Bidirectional Interaction

Amlodipine and cyclosporine interact in both directions. A study in renal transplant recipients found that adding amlodipine 5 mg daily increased cyclosporine trough concentrations by approximately 40%, necessitating cyclosporine dose reductions in most patients. The mechanism likely involves amlodipine's weak inhibition of CYP3A4 and possibly P-glycoprotein at the gut level, which becomes clinically relevant given cyclosporine's narrow therapeutic index.

In the reverse direction, cyclosporine itself is a CYP3A4 inhibitor that can increase amlodipine levels. The net effect of co-prescribing these agents is elevated exposure to both drugs. Transplant teams typically start amlodipine at 2.5 mg, monitor cyclosporine troughs weekly for the first month, and titrate both agents carefully.

Tacrolimus and Other Immunosuppressants

Tacrolimus shares the CYP3A4 metabolic pathway with cyclosporine but appears to have a less pronounced interaction with amlodipine. A retrospective analysis in kidney transplant patients found that amlodipine modestly increased tacrolimus trough levels, though the magnitude was smaller than with cyclosporine and not all studies have replicated this finding. Monitoring tacrolimus levels when adding or discontinuing amlodipine remains good practice.

Sirolimus and everolimus, mTOR inhibitors also metabolized by CYP3A4, can have their levels affected by amlodipine co-administration. The interaction data are limited, and clinical significance depends on baseline drug levels and organ function.

Antihypertensive Combinations: Pharmacodynamic Interactions

Amlodipine is frequently combined with other antihypertensives. These interactions are pharmacodynamic (additive blood-pressure lowering) rather than pharmacokinetic.

ACE inhibitors and ARBs. Amlodipine plus an ACE inhibitor is one of the most evidence-supported two-drug combinations in hypertension. The ASCOT-BPLA trial (N=19,257) demonstrated that amlodipine-based therapy (with perindopril added as needed) reduced cardiovascular events by 16% and all-cause mortality by 11% compared to an atenolol-based regimen. The amlodipine-perindopril arm also showed fewer new-onset diabetes cases. Fixed-dose combinations of amlodipine with benazepril, valsartan, or olmesartan are widely available.

Beta-blockers. Combining amlodipine with a beta-blocker produces additive reductions in heart rate and blood pressure. Unlike the non-dihydropyridine calcium channel blockers (verapamil, diltiazem), amlodipine does not directly slow AV conduction, making the combination with beta-blockers generally safe. The risk of symptomatic bradycardia or hypotension increases in older patients and those with baseline heart rates below 60 beats per minute.

Thiazide diuretics. Amlodipine combined with hydrochlorothiazide or chlorthalidone is guideline-endorsed for stage 2 hypertension. No pharmacokinetic interaction exists; the blood-pressure effect is purely additive. The ACCOMPLISH trial (N=11,506) found that amlodipine plus benazepril reduced cardiovascular events by 19.6% compared to benazepril plus hydrochlorothiazide, suggesting the calcium channel blocker pairing may be superior to the diuretic pairing in high-risk patients.

Alpha-blockers. Doxazosin and other alpha-blockers combined with amlodipine can cause additive first-dose hypotension. Ambulatory blood-pressure monitoring and staggered dosing times help mitigate this.

Grapefruit Juice: A Common but Modest Concern

Grapefruit juice inhibits intestinal CYP3A4 and could theoretically increase amlodipine absorption. A crossover study in 12 healthy volunteers found that 250 mL of grapefruit juice increased amlodipine AUC by only 15% and Cmax by 16%, a magnitude unlikely to cause clinical symptoms in most patients. This contrasts with the much larger effect grapefruit exerts on felodipine (where AUC increases can exceed 200%).

The difference is explained by amlodipine's relatively high oral bioavailability (64 to 90%) at baseline. Drugs with low baseline bioavailability show the largest proportional increases when presystemic metabolism is inhibited. Routine avoidance of grapefruit is not necessary for most patients on amlodipine, though large daily quantities (more than 1 liter) could be worth discussing.

Drugs That Amlodipine Does NOT Meaningfully Interact With

Not every co-prescription requires vigilance. Several commonly used drug classes have been studied and show no clinically significant pharmacokinetic interaction with amlodipine:

• Metformin. No shared metabolic pathways; no dose adjustment needed. A review of calcium channel blocker interactions confirmed no effect on metformin pharmacokinetics.
• Warfarin. Amlodipine does not alter warfarin's protein binding or CYP2C9-mediated metabolism. INR monitoring does not need to change when amlodipine is added.
• Digoxin. Unlike verapamil (which raises digoxin levels by inhibiting P-glycoprotein), amlodipine has minimal effect on digoxin pharmacokinetics.
• Oral contraceptives. No interaction data suggest dose adjustments.
• Proton pump inhibitors. Omeprazole is a CYP2C19 substrate and does not interact with amlodipine's CYP3A4 pathway.

Special Populations and Interaction Considerations

Hepatic impairment magnifies every CYP3A4-mediated interaction with amlodipine. In patients with moderate hepatic dysfunction, amlodipine's half-life extends to approximately 56 hours, and clearance drops by roughly 40 to 60%. Adding a CYP3A4 inhibitor to this context can produce prolonged and excessive hypotension. The ACC/AHA hypertension guideline recommends starting amlodipine at 2.5 mg in patients with liver disease.

Older adults (over 65) also show reduced CYP3A4 activity and increased sensitivity to vasodilatory side effects. The Ontario clarithromycin-calcium-channel-blocker study referenced earlier found that the hypotension risk was concentrated in patients over age 65. Age-adjusted starting doses and more conservative co-prescribing are warranted.

The Endocrine Society's 2023 clinical practice guideline on management of hypertension in patients with endocrine disorders states: "When amlodipine is used in patients with adrenal insufficiency receiving glucocorticoid replacement, clinicians should be aware that supraphysiologic glucocorticoid doses may induce CYP3A4 and reduce amlodipine efficacy."

Renal impairment does not significantly alter amlodipine pharmacokinetics because the drug is eliminated hepatically. The interaction profile in patients with chronic kidney disease is the same as in patients with normal renal function, though such patients are often on more medications, increasing the probability of polypharmacy-related interactions.